These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 22310628)
1. The clinical significance of human leukocyte antigen antibody development in kidney transplantation. Lee PC; Chen YL; Chou TC; Wang WM; Wang JD; Hung CJ; Chang SS; Lin YJ; Chan RH Transplant Proc; 2012 Jan; 44(1):264-6. PubMed ID: 22310628 [TBL] [Abstract][Full Text] [Related]
2. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation. Lee PC; Ozawa M Clin Transpl; 2007; ():219-26. PubMed ID: 18642453 [TBL] [Abstract][Full Text] [Related]
3. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients. Meng HL; Jin XB; Li XT; Wang HW; Lü JJ Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748 [TBL] [Abstract][Full Text] [Related]
4. Role of human leukocyte antigen, donor-specific antibodies, and their impact in renal transplantation. Thiyagarajan UM; Bagul A; Frost J; Horsburgh T; Nicholson ML Transplant Proc; 2012 Jun; 44(5):1231-5. PubMed ID: 22663991 [TBL] [Abstract][Full Text] [Related]
5. Eighteen-year follow-up of a retrospective study of HLA antibody on kidney graft survival. Lee PC; Ozawa M; Hung CJ; Lin YJ; Chang SS; Chou TC Transplant Proc; 2009; 41(1):121-3. PubMed ID: 19249493 [TBL] [Abstract][Full Text] [Related]
6. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Lachmann N; Terasaki PI; Budde K; Liefeldt L; Kahl A; Reinke P; Pratschke J; Rudolph B; Schmidt D; Salama A; Schönemann C Transplantation; 2009 May; 87(10):1505-13. PubMed ID: 19461487 [TBL] [Abstract][Full Text] [Related]
7. Human leukocyte antigen and major histocompatibility complex class I-related chain A antibodies after kidney transplantation in Turkish renal transplant recipients. Seyhun Y; Ozdilli K; Oguz F; Karahan G; Onal E; Turkmen A; Eldegez U; Nane I; Çalişkan Y; Bakkaloglu H; Carin M Transplant Proc; 2012; 44(6):1660-6. PubMed ID: 22841239 [TBL] [Abstract][Full Text] [Related]
8. Impact of HLA antibodies on graft survival in long-term renal recipients with functional grafts. Zeng Y; Liu Z; Liu Y; Fan Y; Guo Y; Qiu J Urol Int; 2014; 92(3):328-33. PubMed ID: 24480999 [TBL] [Abstract][Full Text] [Related]
9. Analysis of transplant outcomes after five or six human leukocyte antigen-mismatched living donor kidney transplantation. Lee HS; Kim MS; Kim YS; Joo DJ; Ju MK; Kim SJ; Kim SI; Huh KH; Park K Transplant Proc; 2012 Jan; 44(1):273-5. PubMed ID: 22310631 [TBL] [Abstract][Full Text] [Related]
10. Cyclosporine or tacrolimus: which is the better partner for myfortic or cellcept? Lee PC; Chang SS; Shieh SC; Wu ZC; Wang WM; Wang JD; Hung CJ; Lin YJ; Chou TC; Chan RH Transplant Proc; 2012 Jan; 44(1):137-9. PubMed ID: 22310598 [TBL] [Abstract][Full Text] [Related]
11. Post transplant development of MICA and anti-HLA antibodies is associated with acute rejection episodes and renal allograft loss. Panigrahi A; Gupta N; Siddiqui JA; Margoob A; Bhowmik D; Guleria S; Mehra NK Hum Immunol; 2007 May; 68(5):362-7. PubMed ID: 17462503 [TBL] [Abstract][Full Text] [Related]
12. Understanding the significance of low-level preformed donor-specific anti-HLA antibodies in renal transplant patients. Wu P; Everly MJ; Jin J; Mao Y; Chen J Clin Transpl; 2011; ():365-8. PubMed ID: 22755432 [TBL] [Abstract][Full Text] [Related]
13. Relevance of posttransplant flow cytometric T- and B-cell crossmatches in tacrolimus-treated renal transplant patients. Lenaers JI; Christiaans MH; Voorter CE; van Hooff HP; van den Berg-Loonen EM Transplantation; 2006 Nov; 82(9):1142-7. PubMed ID: 17102764 [TBL] [Abstract][Full Text] [Related]
14. Effects of antibody induction on transplant outcomes in human leukocyte antigen zero-mismatch deceased donor kidney recipients. Kuo HT; Huang E; Emami S; Pham PT; Wilkinson AH; Danovitch GM; Bunnapradist S Transplantation; 2012 Mar; 93(5):493-502. PubMed ID: 22306574 [TBL] [Abstract][Full Text] [Related]
15. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Lee PC; Zhu L; Terasaki PI; Everly MJ Transplantation; 2009 Aug; 88(4):568-74. PubMed ID: 19696641 [TBL] [Abstract][Full Text] [Related]
16. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts. Cooper JE; Gralla J; Chan L; Wiseman AC Clin Transpl; 2011; ():359-64. PubMed ID: 22755431 [TBL] [Abstract][Full Text] [Related]
17. Detailed examination of HLA antibody development on renal allograft failure and function. Zhu L; Lee PC; Everly MJ; Terasaki PI Clin Transpl; 2008; ():171-87. PubMed ID: 19711514 [TBL] [Abstract][Full Text] [Related]
18. A novel post-transplant alloantibody surveillance and intervention strategy that improves graft outcomes in sensitized renal transplant recipients. Kimball PM; King A Clin Transpl; 2011; ():369-72. PubMed ID: 22755433 [TBL] [Abstract][Full Text] [Related]
19. The effect of donor-recipient relationship on long-term outcomes of living related donor renal transplantation. Choi JY; Kwon OJ; Kang CM Transplant Proc; 2012 Jan; 44(1):257-60. PubMed ID: 22310626 [TBL] [Abstract][Full Text] [Related]
20. Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: a Collaborative Transplant Study report. Süsal C; Döhler B; Opelz G Hum Immunol; 2009 Aug; 70(8):569-73. PubMed ID: 19375472 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]